Sanofi India Ltd

Sanofi Healthcare India Private Limited, a member of Sanofi India's promoter group, has agreed to acquire up to 3,500,000 equity shares from Hoechst GmbH, another promoter. This inter-se transfer represents up to 15.20% of Sanofi India's existing paid-up equity share capital. The transaction is exempt from an open offer under SEBI Takeover Regulations 10(1)(a)(iii) and is scheduled to occur on or after September 24, 2026. The acquisition price will not exceed 25% above the 60-day volume-weighted average market price of ₹3,228.06 per share, as the shares are frequently traded.

Sanofi India Ltd announced that the Supreme Court of India dismissed its petition to quash criminal proceedings. The ruling pertains to the maintainability of criminal prosecution against the company, even without individual employee involvement. The case involves pharmaceutical supplies to BARC, Mysore, between 2012-2015 and allegations of conspiracy to influence procurement. The Supreme Court has not made any findings of guilt or adjudicated on the merits of the case. The criminal complaint remains pending for trial. The company is assessing the judgment and its next litigation strategy, noting no immediate penalty or operational restrictions.

Sanofi India Ltd has received a Show Cause Notice from the Additional Commissioner of CGST and CX, Mumbai East, alleging misclassification of certain products. The company is accused of classifying products at a concessional rate of 5% instead of 12% for the financial year 2020-21. The notice proposes a tax liability of ₹36,38,70,979 and a penalty of the same amount, totaling ₹72,77,41,958. Sanofi India is currently reviewing the notice with its tax advisors and will submit a reply within the stipulated time. The company does not anticipate any adverse financial or operational impact from this notice.

Sanofi India Ltd has received an order from the Deputy Commissioner, Central Goods & Service Tax, Margao-Goa, approving a GST refund of ₹1,32,93,535. The company had filed an application to receive this refund without it being adjusted against an outstanding demand of ₹75,63,190. The tax authority has dropped the proposed adjustment of the outstanding demand, sanctioning the full refund. Sanofi India stated that this development has no material impact on its financial, operational, or other activities.

Sanofi India Ltd has received an order from the Assistant Commissioner of Income Tax, Mumbai, giving effect to a favorable appellate order from the Commissioner of Income Tax Appeal (CIT(A)). The order, received on August 11, 2026, vacates a demand of ₹72,71,510 related to proceedings under Section 201 of the Income-tax Act, 1961. The appeal was against the non-deduction of TDS on year-end provisions for the Assessment Year 2019-20. The company had previously informed the stock exchanges about the CIT(A) order on July 3, 2026. This resolution has no material impact on the company's financial or operational activities.

Sanofi India Limited announced its unaudited financial results for the quarter and half-year ended June 30, 2026. The company reported domestic net sales growth of 8% and total net sales growth of 6% for Q2 2026 compared to Q2 2025. The Insulin portfolio showed strong performance with 14% growth, driven by key products like Lantus®, Toujeo®, and Apidra®. Public sector business accelerated by 70%. Profits before tax and exceptional items increased by 19% to ₹112 crores. The Board also approved the re-constitution of the Stakeholders Relationship Committee and Risk Management Committee, and noted the stepping down of Mr. Rachid Ayari as Whole Time Director and CFO.

Sanofi India Limited announced its financial results for the quarter ended June 30, 2026. The company reported a 19% increase in profits before tax and exceptional items to ₹112 crores, up from ₹94 crores in Q2 2025. Total net sales grew by 6%, driven by an 8% domestic net sales increase. The Diabetes portfolio, particularly the Insulin segment, showed strong performance with double-digit growth of 14%. Profit before tax as a percentage of net sales improved to 27% from 24% in the prior year, attributed to a favorable product mix and cost management. The Board also approved the re-constitution of the Stakeholders Relationship Committee and Risk Management Committee, and noted the stepping down of the CFO.

Sanofi India Limited announced its unaudited financial results for the quarter and half-year ended June 30, 2026. The company reported domestic net sales growth of 8% and total net sales growth of 6% compared to Q2 2025. The Insulin portfolio showed double-digit growth of 14%, with specific products like Lantus®, Toujeo®, and Apidra® performing well. Profits before tax and exceptional items increased by 19% to ₹112 crores. The Board of Directors also approved the re-constitution of the Stakeholders Relationship Committee and Risk Management Committee, and noted the stepping down of Mr. Rachid Ayari as Whole Time Director and CFO.

Sanofi India Limited announced its financial results for the quarter ended June 30, 2026. The company reported a 19% increase in profits before tax and exceptional items to INR 112 crores, up from INR 94 crores in Q2 2025. Total net sales grew by 6%, driven by an 8% domestic net sales growth. The Diabetes portfolio, particularly the Insulin segment, showed strong performance with double-digit growth of 14%. Profit before tax as a percentage of net sales improved to 27% from 24%. The Board also approved the reconstitution of the Stakeholders Relationship Committee and Risk Management Committee, and noted the stepping down of the CFO and Whole Time Director.

Sanofi India Ltd's Board of Directors met on August 4, 2026, to approve the unaudited financial results for the quarter and half-year ended June 30, 2026. The company reported strong Q2 2026 performance with domestic net sales up 8% and total net sales up 6% year-on-year. The Diabetes Portfolio, particularly Insulin, showed double-digit growth of 14%. Profits before tax and exceptional items increased by 19% to INR 112 crores, with profit margin improving to 27%. The Board also approved the re-constitution of the Stakeholders Relationship Committee and Risk Management Committee, effective October 1, 2026. Additionally, Mr. Rachid Ayari will step down as Whole Time Director and CFO on September 30, 2026.